Published in final edited form as:

Bioorg Med Chem Lett. 2009 March 15; 19(6): 1749–1752. doi:10.1016/j.bmcl.2009.01.083.

First small molecular inhibitors of *T. brucei* dolicholphosphate mannose synthase (DPMS), a validated drug target in African sleeping sickness

Terry K. Smith^a, Benjamin L. Young^b, Helen Denton^a, David L. Hughes^b, and Gerd K. Wagner^{b,*}

^aCentre for Biomolecular Sciences, The North Haugh, The University, St. Andrews, Scotland, UK

^bCentre for Carbohydrate Chemistry, School of Chemical Sciences and Pharmacy, University of East Anglia, Earlham Road, Norwich NR4 7TJ, UK

Abstract

Drug-like molecules with activity against *Trypanosoma brucei* are urgently required as potential therapeutics for the treatment of African sleeping sickness. Starting from known inhibitors of other glycosyltransferases, we have developed the first small molecular inhibitors of dolicholphosphate mannose synthase (DPMS), a mannosyltransferase critically involved in glycoconjugate biosynthesis in *T. brucei*. We show that these DPMS inhibitors prevent the biosynthesis of glycosylphosphatidylinositol (GPI) anchors, and possess trypanocidal activity against live trypanosomes.

Keywords

African sleeping sickness; Trypanosoma; Dolicholphosphate mannose synthase; Enzyme inhibitors

African sleeping sickness, also known as Human African Trypanosomiasis (HAT), is an infectious disease caused by the protozoan parasite *Trypanosoma brucei* (*T. brucei*). The parasite is transmitted by the bite of an infected tsetse fly, multiplies within the bloodstream of the mammalian host, and eventually invades the central nervous system. If untreated, HAT is invariably lethal. Despite becoming close to eradication by the late 1960s,¹ the disease has made a dramatic re-emergence within the last half century, with prevalence in parts of Africa now as high as they were in the 1920s. In 2002 alone, around 48,000 deaths were reported.² The WHO presently records around 17,500 new cases per year,³ with a cumulative rate of 50,000–70,000 cases³ and potentially over 60 million people at risk.²

The situation is further exacerbated by the growing resistance to established drug treatments for HAT, which have long been considered unsatisfactory.² Serious side effects kill between 4% and 10% of patients who receive the arsenical melarsoprol,⁴ introduced in 1949, and the drug fails to cure between 10% and 30% of patients.⁵ The only relatively modern anti-HAT drug, the ornithine decarboxylase inhibitor eflornithine, is expensive, difficult to administer, and only effective against *T. brucei gambiense*.⁶ Thus, HAT has been described as one of the most neglected diseases of mankind,⁷ and novel therapeutic approaches to HAT are urgently needed.²

The *T. brucei* parasite is covered in a dense cell-surface coat of ~5 million variant surface glycoprotein (VSG) dimers^{8,9} which acts as a physical diffusion barrier for components of the innate immune system.¹⁰ The VSG coat undergoes constant antigenic variation,^{11,12} as the parasite switches between ~1000 immunologically distinct VSG genes,¹³ thus staying one step ahead of the host immune system. All VSG variants are linked to the trypanosomal plasma membrane via glycosylphosphatidylinositol (GPI) anchors (Fig. 1). Genetic¹⁴⁻¹⁶ and chemical^{17,18} studies show that GPI anchor biosynthesis is essential for viability of the bloodstream form of *T. brucei*, thus validating it as a drug target against HAT.¹⁹ Small molecular inhibitors of enzymes involved in GPI anchor biosynthesis therefore hold great promise as novel anti-trypanosomal agents.

GPI anchor biosynthesis in *T. brucei* involves three mannosyltransferases (MTs) on the luminal face of the endoplasmic reticulum, which catalyze the assembly of the trimannoside core structure (Fig. 1).^{20,21} All three of these MTs use dolicholphosphate mannose (Dol-P-Man) as their donor substrate, whose biosynthesis from dolicholphosphate (Dol-P) and the sugar-nucleotide GDP-mannose (GDP-Man) is catalyzed by another mannosyltransferase, dolicholphosphate mannose synthase (DPMS). All *T. brucei* VSG variants also contain at least one *N*-glycan, which requires another four Dol-P-Man-dependant mannosyltransferases for the formation of its lipid-linked oligosaccharide precursor.²²⁻²⁴ Consequently, *T. brucei* is doubly dependant upon Dol-P-Man for the synthesis of mature, *N*-glycosylated and GPI-anchored VSGs, and this double dependency makes DPMS an excellent target for inhibition of VSG biosynthesis. Recently, *T. brucei* DPMS has also been validated genetically as a drug target.²⁵

Despite its promise as a therapeutic target, no inhibitors for *T. brucei* DPMS have been reported to date. The rational design of such inhibitors is complicated by the absence of a crystal structure for *T. brucei* DPMS at present. In search of a suitable lead structure for the development of DPMS inhibitors, we noticed striking structural similarities among small molecular inhibitors for other glycosyltransferases²⁶⁻²⁸ and sugar-nucleotide-dependent glycoprocessing enzymes.²⁹⁻³¹ Several such inhibitors contain a rhodanine (2-thioxothiazolidin-4-one) scaffold, and derivatives of rhodanine-3-acetic acid **1** (Scheme 1) have been reported as inhibitors of the *E. coli* glycosyltransferase MurG^{26,27} and the *C. albicans* protein mannosyltransferase 1 (PMT1).²⁸ It has been suggested that the thiazolidinone ring can act as a mimic of the pyrophosphate group,^{26,29-31} and that this mimicry may explain the inhibitory activity of thiazolidinone derivatives towards sugar-nucleotide-dependent enzymes. As DPMS is dependent on the sugar-nucleotide donor GDP-mannose, we reasoned that the thiazolidinone scaffold may also represent a good starting point for the development of DPMS inhibitors.

Herein, we describe the successful application of this strategy. We have prepared a small library of 5-benzylidene rhodanine-3-acetic acid analogs of the general structure **2**, and report herein their inhibitory activity against *T. brucei* DPMS and GPI anchor biosynthesis as well as their trypanocidal activity against live trypanosomes.

The target rhodanine-3-acetic acid derivatives **2a-j** (Scheme 1, Table 1) were prepared by Knoevenagel condensation of rhodanine-3-acetic acid **1** and substituted benzaldehydes **3a-j**. To simplify the preparation and isolation of the target compounds, we explored different solvents and catalytic bases for this reaction, including DMF/sodium acetate, toluene/piperidine and ethanol/piperidine.^{28,32} In our hands, the ethanol/piperidine system was the most practical one, with short reaction times and straightforward product isolation. Under these conditions, all 5-benzylidene rhodanine-3-acetic acid derivatives precipitated from the ethanolic solution upon cooling to room temperature, and could be collected by simple filtration.³³ Thus, all target compounds (Table 1) were obtained as yellow or yellow-orange

solids in generally good yields. Remarkably, this procedure was also applicable to benzaldehydes containing a free phenolic hydroxyl group (e.g., **2f**, **2g**). This was particularly important as all attempts to prepare these analogs by debenzylolation of the corresponding benzyloxy derivatives (e.g., **2b**, **2c**) had failed.

Fortuitously, our synthetic protocol provided benzylidene thiazolidinone **2b** in crystalline form which allowed the unambiguous determination of its three-dimensional structure (Fig. 2).³⁴ This is of particular interest, as in previous reports of structurally related thiazolidinones as glycosyltransferase inhibitors there had been ambiguity about the configuration of the exocyclic double bond, despite its obvious importance for structure–activity relationships.^{26,27} In our structure, the rhodanine acetic acid molecule **2b** is essentially planar, with only the carboxy group out of plane and coordinating to one molecule of ethanol. The exocyclic double bond exists in the *Z* configuration, which for arylidene rhodanines has been reported as the thermodynamically stable configuration.^{35,36}

In an initial biological screen, all target compounds were tested for inhibition of recombinant *T. brucei* DPMS in *E. coli* membranes (Table 1)³⁷. At 1 mM, several thiazolidinone derivatives significantly inhibited *T. brucei* DPMS. A large benzyloxy substituent in position R² and/or R³ appears to be advantageous for DPMS inhibition (**2b–d**), while a small polar substituent is less well tolerated in these positions (**2f** and **2g**), as are rigid R³ substituents (e.g., nitrile **2h**, acetylene **2j**). Intriguingly, however, a polar substituent is beneficial for inhibitory activity when placed at the 2-position (R¹), and the 2-hydroxy regioisomer **2e** is among the most potent DPMS inhibitors in this series.

Next, compounds **2a–j** were tested for their trypanocidal activity against cultured bloodstream form *T. brucei*.³⁸ Importantly, the in vitro activity of several thiazolidinones against DPMS did translate into in vivo trypanocidal activity against live trypanosomes. In particular, the 3-benzyloxy-substituted analog **2c** and the 2-hydroxy regioisomer **2e** showed trypanocidal activity with ED₅₀ values in the medium micromolar range. However, only moderate activity was observed for some of the other potent DPMS inhibitors, notably the benzyloxy-substituted analogs **2b** and **2d**. The limited cellular activity of these DPMS inhibitors may be due to various factors, including limited cell penetration, which are currently being investigated.

In order to assess the parasite/host selectivity of these thiazolidinones, analogs **2a–f** and **2j** were tested at two concentrations (0.1 and 1.0 mM final) for their cytotoxicity against HeLa cells.³⁸ Pleasingly, none of these thiazolidinones showed any cytotoxic effect, with the exception of **2b** and **2j** (20% inhibition at 1.0 mM, compared to DMSO-only control), suggesting low mammalian cytotoxicity (ED₅₀ > 1.0 mM) and a promising margin of selectivity for *T. brucei*.

In order to gain further insight into the mode of action of these novel DPMS inhibitors, we investigated the effect of the thiazolidinones on GPI anchor biosynthesis in a *T. brucei* cell-free-system (Fig. 3).³⁹ This assay monitors the DPMS-catalyzed formation of Dol-P-Man (lane 1) as well as the downstream formation of mannosylated GPI intermediates (lane 2). As expected, the potent DPMS inhibitor **2d** abolished the formation of Dol-P-Man almost completely, and significantly reduced the formation of downstream GPI intermediates. A similar effect was observed for the analog **2f** (Fig. 3).

Interestingly, thiazolidinones **2b** and **2e** did not affect Dol-P-Man production in the cell-free system, but did potently inhibit the formation of mannosylated GPI intermediates. Thus, the strong inhibitory effect of **2b** and **2e** on GPI anchor biosynthesis in the cell-free system may be due to inhibition of one or more GPI biosynthetic enzymes early in the pathway, for

example, the GlcNAc transferase, de-N-acetylase or the first mannosyltransferase (MT1). Importantly, all of these enzymes represent therapeutic targets in their own right, and their inhibition may contribute to the trypanocidal activity of **2b** and **2e**.

In summary, we have identified the first small molecular inhibitors of trypanosomal DPMS. We demonstrate that DPMS inhibitors compromise trypanosomal GPI anchor biosynthesis in a cell-free system, and that inhibition of DPMS is a promising strategy for the development of anti-trypanosomal agents. Work on the optimization of these initial lead compounds with regard to their DPMS inhibitory potency as well as cellular activity is ongoing. Thiazolidinones **2b**, **2d** and **2e** in particular are promising candidates for further development because of their respective activities against trypanosomal DPMS and GPI anchor biosynthesis.

Acknowledgments

We thank the EPSRC National Mass Spectrometry Service, Swansea, and Mr. Thomas Pesnot (UEA) for the recording of spectra, and the 2008 MPharm mini-project students in the Wagner group for technical assistance. T.K.S. is supported by a Wellcome Trust Senior Research Fellowship (067441).

References and notes

1. Delespaulx V, de Koning HP. Drug Resist. Update. 2007; 10:30.
2. Pink R, Hudson A, Annick-Mouries M, Bendig M. Nat. Rev. Drug Discov. 2005; 4:727. [PubMed: 16138106]
3. The World Health Organisation. African trypanosomiasis. WHO publications; Geneva: Fact sheet No. 259 (revised August 2006)
4. Pepin J, Guern C, Ethier L, Milord F, Mpia B, Mansinsa D. Lancet. 1989; 1:1246. [PubMed: 2566790]
5. Burri C, Keiser J. Trop. Med. Int. Health. 2001; 6:412. [PubMed: 11348536]
6. Burri C, Brun R. Parasitol. Res. 2003; 90:S49. [PubMed: 12811548]
7. Stich A, Barrett MP, Krishna S. Trends Parasitol. 2003; 19:195. [PubMed: 12763420]
8. Ferguson MAJ, Cross GA. J. Biol. Chem. 1984; 259:3011. [PubMed: 6699005]
9. Ferguson MAJ, Low MG, Cross GA. J. Biol. Chem. 1985; 260:14547. [PubMed: 4055788]
10. Ferguson MAJ. Proc. Natl. Acad. Sci. U.S.A. 2000; 97:10673. [PubMed: 11005849]
11. Cross GAM. BioEssays. 1996; 18:283. [PubMed: 8967896]
12. Aitchison N, Talbot S, Shapiro J, Hughes K, Adkin C, Butt T, Sheader K, Rudenko G. Mol. Microbiol. 2005; 57:1608. [PubMed: 16135228]
13. Blum ML, Down JA, Gurnett AM, Carrington M, Turner MJ, Wiley DC. Nature. 1993; 362:603. [PubMed: 8464512]
14. Chang T, Milne KG, Guthrie ML, Smith TK, Ferguson MAJ. J. Biol. Chem. 2002; 277:50176. [PubMed: 12364327]
15. Nagamune K, Nozaki T, Maeda Y, Ohishi K, Fukuma T, Hara T, Schwarz RT, Sutterlin C, Brun R, Riezman H, Kinoshita T. Proc. Natl. Acad. Sci. U.S.A. 2000; 97:10336. [PubMed: 10954751]
16. Lillico S, Field MC, Blundell P, Coombs GH, Mottram JC. Mol. Biol. Cell. 2003; 14:1182. [PubMed: 12631733]
17. Smith TK, Crossman A, Brimacombe JS, Ferguson MAJ. EMBO J. 2004; 23:4701. [PubMed: 15526036]
18. Crossman A, Smith TK, Ferguson MAJ, Brimacombe JS. Tetrahedron Lett. 2005; 46:7419.
19. Ferguson MAJ, Brimacombe JS, Brown JR, Crossman A, Dix A, Field RA, Guthrie MLS, Milne KG, Sharma DK, Smith TK. Biochim. Biophys. Acta. 1999; 1455:327. [PubMed: 10571022]
20. Menon AK, Mayor S, Schwarz RT. EMBO J. 1990; 9:4249. [PubMed: 2148289]
21. Schwarz RT, Mayor S, Menon AK, Cross GAM. Biochem. Soc. Trans. 1988; 17:746.
22. Helenius A, Aeby M. Annu. Rev. Biochem. 2004; 73:1019. [PubMed: 15189166]

23. Orlean P. *Biochem. Cell Biol.* 1992; 70:438. [PubMed: 1333231]
24. Schutzbach JS. *Glycoconjugate J.* 1997; 14:175.
25. Denton, H.; Fyffe, S. A.; Smith, T. K., submitted for publication.
26. Helm JS, Hu Y, Chen L, Gross B, Walker SJ. *Am. Chem. Soc.* 2003; 125:11168.
27. Hu Y, Helm JS, Chen L, Ginsberg C, Gross B, Kraybill B, Tiyanont K, Fang X, Wu T, Walker S. *Chem. Biol.* 2004; 11:703. [PubMed: 15157881]
28. Orchard MG, Neuss JC, Galley CMS, Carr A, Porter DW, Smith P, Scopes DIC, Haydon D, Vousden K, Stubberfield CR, Young K, Page M. *Bioorg. Med. Chem. Lett.* 2004; 14:3975. [PubMed: 15225710]
29. Soltero-Higgin M, Carlson EE, Phillips JH, Kiessling LL. *J. Am. Chem. Soc.* 2004; 126:10532. [PubMed: 15327298]
30. Carlson EE, May JF, Kiessling LL. *Chem. Biol.* 2006; 13:825. [PubMed: 16931332]
31. Andres CJ, Bronson JJ, D'Andrea SV, Deshpande MS, Falk PJ, Grant-Young KA, Harte W, Ho H-T, Misco PF, Robertson JG, Stock D, Sun Y, Walsh AW. *Bioorg. Med. Chem. Lett.* 2000; 10:715. [PubMed: 10782671]
32. Irvine MW, Patrick GL, Kewney J, Hastings SF, MacKenzie SJ. *Bioorg. Med. Chem. Lett.* 2008; 18:2032. [PubMed: 18304812]
33. Representative procedure for **2b** (all thiazolidinones **2a–j** were characterized by NMR and HRMS): A mixture of rhodanine-3-acetic acid **1** (0.51 g, 2.61 mmol), 4-benzoyloxybenzaldehyde **3b** (0.60 g, 2.83 mmol) and a drop of piperidine in absolute ethanol (25 ml) was heated to reflux for 2 h. Upon cooling of the reaction to room temperature, a precipitate formed which was collected by filtration, washed with cold ethanol, and dried under vacuum to provide 0.78 g (76%) of **2b** as yellow crystals. Melting point: 202–205°. δ_{H} (400 MHz, d_6 -DMSO) 4.72 ppm (s, 3H), 5.21 (s, 3H), 7.20–7.22 (m, 2H), 7.34–7.50 (m, 5H), 7.64–7.66 (m, 2H), 7.86 (s, 1H). δ_{C} (75.5 MHz, d_6 -DMSO) 45.0, 69.7, 116.1, 118.8, 125.7, 128.0, 128.3, 128.7, 133.3, 134.3, 136.6, 161.1, 166.7, 167.6, 193.4. m/z (ESI) 384.0370 $[\text{M}-\text{H}]^-$, $\text{C}_{10}\text{H}_{14}\text{O}_4\text{NS}_2$ requires 384.0365.
34. The X-ray coordinates for **2b** have been deposited at the Cambridge Crystallographic Data Centre, deposition number CCDC 715650.
35. Ishida T, In Y, Inoue M, Ueno Y, Tanaka C. *Tetrahedron Lett.* 1989; 30:959.
36. Ohishi Y, Mukai T, Nagahara M, Yajima M, Kajikawa N, Miyahara K, Takano T. *Chem. Pharm. Bull.* 1990; 38:1911. [PubMed: 2125247]
37. Full experimental details will be published elsewhere. Briefly, *E. coli* membranes containing recombinantly expressed, full-length (membrane-bound) *T. brucei* DPMS (70 ng/ml total protein) were added to a reaction mix (60 ml) of Na–Hepes (50 mM, pH 7.4), KCl (25 mM), MgCl_2 (5 mM), MnCl_2 (5 mM), dehydrofarnesol-phosphate (1 mg), GDP- $[\text{}^3\text{H}]\text{Man}$ (0.25 mCi/1 mM), and inhibitor (1 mM), all in the presence of 0.1% *n*-octyl-glucopyranoside. The reaction was incubated at 30 °C for 10 min, quenched, and lipids extracted by the addition of $\text{CHCl}_3\text{:MeOH}$ (1:1). The resulting supernatant was dried and partitioned between butan-1-ol and water, a portion butan-1-ol was counted as a measure of dehydrofarnesol-phosphate- $[\text{}^3\text{H}]\text{Man}$ product.
38. The trypanocidal activity of all inhibitors against cultured bloodstream *T. brucei* (strain 427) and their cytotoxicity against HeLa cells was determined using the Alamar Blue™ viability test as described in Mikus J, Steverding D. *Parasitol. Int.* 2000; 48:265. [PubMed: 11227767]
39. Cell-free system assay of GPI biosynthesis in brief: Membranes of bloodstream *T. brucei* (variant 117) were prepared as described previously (Smith TK, et al. *EMBO J.* 1999; 18:5922. [PubMed: 10545104]) snap frozen in liquid nitrogen and stored at –80 °C until needed. Per assay, 1×10^7 cell equivalents were used. Membranes were washed twice in 10 ml of wash buffer (50 mM Na–Hepes, pH 7.4, 25 mM KCl, 5 mM MgCl_2 , 100 mM tosyl-L-lysine chloromethyl ketone (TLCK), and 1 $\mu\text{g/ml}$ leupeptin), resuspended by sonication in 20 ml of 2 $\times$ incorporation buffer (2 times concentrated wash buffer containing 10 mM MnCl_2 , 1 mg/ml tunicamycin and 1 mM dithiothreitol) and added to a reaction tube containing an equal volume of GDP- $[\text{}^3\text{H}]\text{Man}$ (0.3 mCi per 10^7 cell equivalents), 1 mM UDP-GlcNAc and thiazolidinone inhibitor candidate (in DMSO, final concentration 1 mM). The cell-free system was then sonicated briefly, incubated at 30 °C for 1 h, and the reaction stopped by the addition of $\text{CHCl}_3\text{:MeOH}$ (1:1). Glycolipid products were recovered by extraction into $\text{CHCl}_3\text{:MeOH:H}_2\text{O}$ (10:10:3), evaporated to dryness,

partitioned between butan-1-ol and water, and analyzed by HPTLC (CHCl_3 :MeOH: NH_4OAc (1 M):conc. NH_3 : H_2O 180:140:9:9:23). Dried HPTLC plates were sprayed with $\text{En}^3\text{Hance}^{\text{TM}}$, and radiolabeled components were visualized by fluorography at -80°C using Kodak Biomax MS films with an intensifying screen.

Figure 1.

The central role of DPMS for the biosynthesis of GPI anchors in *T. brucei*. VSG: variant surface glycoprotein; GPI: glycosylphosphatidylinositol; GDP-Man: guanosine diphosphate mannose; Dol-P-Man: dolicholphosphate mannose; DPMS: dolicholphosphate mannose synthase.

Figure 2. The crystal structure of the representative 5-benzylidene thiazolidinone **2b**, in complex with one molecule of ethanol, shows the exocyclic double bond (C2=C20) in the *Z* configuration.

Figure 3.

Differential effects of 5-benzylidene thiazolidinones **2a–j** on DPMS and GPI anchor biosynthesis (M1: Man α 1-4GlcNH₂-PI; M2: Man α 1-6Man α 1-4GlcNH₂-PI; M3: Man α 1-2Man α 1-6Man α 1-4GlcNH₂-PI; aM3: Man α 1-2Man α 1-6Man α 1-4GlcNH₂-(acyl)PI; A': ethanolamine-P-Man α 1-2Man α 1-6Man α 1-4GlcNH₂-PI).

Scheme 1.

Synthesis of the target 5-benzylidene rhodanine-3-acetic acid derivatives **2a-j**. Reagents and conditions: NH_4OAc , DMF, 80 °C, 3 h (**2a**) or EtOH, piperidine, 80 °C, 3–6 h (**2b-j**). For substituents R^1 – R^3 see Table 1.

Table 1Biological activity of thiazolidinones **2a-j** (Scheme 1)

Compound	R ¹	R ²	R ³	Residual DPMS activity (%) ^a	Trypanocidal activity (ED ₅₀) ^b
2a	H	H	H	42 (±5)	232 (±12)
2b	H	H	BnO	10 (±2)	338 (±31)
2c	H	BnO	H	23 (±3)	96 (±5)
2d	H	BnO	BnO	20 (±4)	492 (±24)
2e	OH	H	H	23 (±8)	107 (±12)
2f	H	H	OH	70 (±4)	427 (±19)
2g	H	OH	H	90 (±5)	345 (±23)
2h	H	H	CN	73 (±6)	244 (±17)
2i	H	H	Cl	86 (±5)	398 (±19)
2j	H	H	CCH	94 (±7)	>1000

^aResidual DPMS activity in the presence of 1 mM inhibitor, relative to control experiments without inhibitor (activity = 100 ± 3%).^bAll ED₅₀ values are in μM against cultured bloodstream *T. brucei*. All experiments were carried out at least in duplicate.